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Abstract. Background: We performed a pilot study, looking at
the COX-2 inhibitor celecoxib, on newly diagnosed prostate
cancer patients in the neo-adjuvant setting using DNA
microarray analysis. Patients and Methods: This was a single-
blinded, randomized controlled phase II presurgical (radical
prostatectomy) 28-day trial of celecoxib versus no drug in
patients with localized T1-2 N0 M0 prostate cancer. cDNA
microarray analysis was carried out on prostate cancer biopsies
taken from freshly obtained radical prostatectomy samples.
Results were confirmed by qPCR analysis of a selection of
genes. Results: Multiple genes were differentially expressed in
response to celecoxib treatment. Statistical analysis of
microarray data indicated 24 genes were up-regulated and 4
genes down-regulated as a consequence of celecoxib treatment.
Gene changes e.g. survivin, SRP72kDa, were associated with
promoting apoptotic cell death, enhancement of antioxidant
processes and tumour suppressor function (p73 and cyclin B1
up-regulation). Conclusion: Celecoxib at 400 mg b.i.d. for 4
weeks perioperatively gave rise to changes in gene expression in
prostate cancer tissue consistent with enhancement of apoptosis
and tumour suppressor function. Given the short time interval
for the duration of this study, the data are encouraging and
provide a good rationale for conducting further trials of
celecoxib in prostate cancer.
Prostate cancer is the commonest non-dermatological cancer in
men in Western countries (1) and novel strategies of
management are badly needed. Cyclooxygenase-2 (COX-2) is
intimately involved in the development and progression of a
variety of malignancies, including prostate cancer. COX-2 has
been shown to interact with angiogenic, apoptotic, proliferative,
invasive, metastatic and other pathways involved in cancer
evolution (2). Chronic inflammation and oxidative stress are key
players in COX-2-dependent carcinogenesis. COX-2 has been
shown to be an independent predictor of prostate cancer
progession following radical prostatectomy (3). Moreover, the
outcome of radiotherapy in prostate cancer patients has been
shown to be associated with COX-2 expression, whereby high
levels were indicative of treatment failure (4). Celecoxib is a
selective COX-2 inhibitor (coxib) that appears to have an
anticancer effect in numerous in vivo and in vitro models.
Coxibs, most notably celecoxib, also exert their anti-cancer
effects via COX-2-independent mechanisms including
interference with Akt (signal transduction), NF-κB
(inflammatory mediator of tumorigenesis) and other mediators
of cancer development and progression. The end result of both
COX-2-dependent and COX-2-independent actions is an
inhibition of cancer at multiple stages (2). Presently, the superior
anticancer and cardiovascular safety profiles of celecoxib make
it the coxib of choice for clinical trials. 
The purpose of this study was to investigate the effects of
celecoxib in early prostate cancer. Patients were randomized
to 400 mg celecoxib twice daily (b.i.d.) versus no drug for 4
weeks prior to radical prostatectomy (RP). We initially
assessed the effects of the treatment on markers of
proliferation, apoptosis and angiogenesis using paraffin-
embedded tissue taken from the RP specimens from the
patients in this clinical trial (5). We then went on to assess the
effects of celecoxib on gene expression profiling of prostate
cancer by subjecting samples from drug-treated and control
patients to DNA microarray analysis. Our overall aim was,
therefore, to conduct a pilot study investigating the effects of
celecoxib on the gene expression profiling (GEP) of tumour
biopsies taken from patients with localized prostate cancer.
Patients and Methods
Patient selection. The study was a single-blinded, randomized,
controlled phase II pre-surgical trial of celecoxib versus no drug
for 28 days prior to radical prostatectomy (RP) for patients with
localized (T1-2 N0 M0) prostate cancer. We used a 2:1 block
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randomization, hence the difference in numbers of controls and
treated patients. The power calculation was based on this and the
use of a 2:1 randomization schedule meant we had greater
numbers of treated patients and thus needed fewer patients in the
study to reach the desired power. Ethical approval was obtained
prior to starting the study and all patients recruited to the trial gave
their informed, signed consent. Patients who had decided to
undergo RP as their management option were eligible. Patients
taking NSAIDs or other coxibs were excluded, as were those with
a significant past history of these medications. Patients on
hormonal manipulation and 5-ARIs (e.g. finasteride) were also
excluded, because of the uncertain effects these drugs have on
prostate tumour biology, especially given the recent evidence from
the Prostate Cancer Prevention Trial (6). Patients with
cardiovascular risk factors were also excluded. Baseline clinical
data are indicated in Table I. Although there is no evidence that
COX-2 inhibitors affect cardiovascular risk when taken for periods
of less than one year, and certainly not for a period of 28 days,
patients with cardiovascular risk factors were also excluded. No
patient in our trial suffered an adverse cardiac event. All patients
had Gleason score 6 (3+3) or 7 (3+4) disease and clinically
localized prostate cancer (T1c-T2c N0 M0); the celecoxib and
control groups were therefore matched in terms of histological
grade and stage. There was also no significant difference in PSA
values based the two arms. These baseline clinical data are
indicated in Table I.
Sample collection. Prostatic tissue was collected at the time of
surgery for RP (38 laparoscopic, 7 open procedure for the entire
sample series). The prostate was removed from the body prior to
the vesico-urethral anastomosis being performed then sectioned
vertically and needle/punch biopsies were taken of the peripheral
zone of the prostate in six areas: left apex, right apex, left
midzone, right midzone, right base, and left base. Biopsies were
then rapidly sectioned transversely into three roughly equal parts.
The middle portion was placed in RNAlater® and sent for
subsequent DNA microarray analysis. The mean time from
prostatectomy to RNAlater® (Qiagen Ltd., Crawley, UK)
submersion for sample preservation was ≤15 minutes. Only those
biopsy sections that were histologically confirmed as cancer were
used for cDNA microarray analysis.
GEP using cDNA microarray analysis of prostate cancer biopsies.
Freshly collected core biopsies were rapidly frozen down to –80˚C
for short-term storage prior to extraction. The frozen biopsies in
RNAlater™ solution were thawed on ice and preservation fluid
aspirated. RNA was isolated using the RNeasy method (mini-
column procedure; Qiagen Ltd.) with sample lysis using a
TissueLyser (Qiagen Ltd.). The quality of the resulting RNA was
checked with an Agilent 2100 Bioanalyser using an RNA
NanoLabchip® according to the manufacturer’s instructions (Agilent
Technologies UK Ltd, Stockport, Cheshire, UK). The RNA was
diluted with RNase-free water and quantified using the Nanodrop
spectrophotometer (Nanodrop Technologies Inc.). Due to the
quantity necessary for the microarray analysis and stringent
requirements for quality, RNA from some samples were not suitable
for full analysis and hence, there were 8 control patients and 12
celecoxib-treated patients biopsies used in this analysis.
Labelling reactions were carried out with 3-5 μg total RNA
using the ChipShot Pronto system (Corning Life Sciences,
Schiphol, The Netherlands) according to the manufacturer’s
instructions. A reference labelling reaction was also prepared with
5 μg total Universal Human Reference RNA (Stratagene Europe,
Amsterdam, The Netherlands) and used as an internal control for
the normalization of the microarray data. Cy®3 (test sample) and
Cy®5 (reference) were obtained from GE Healthcare (Amersham,
Buckinghamshire, UK) and used in conjunction with the ChipShot
kit. The amount of Cy®3 and Cy®5 incorporation (frequency of
incorporation; FOI) in the cDNA was quantified using the
Nanodrop Spectrophotometer. Printing of the 3000 Human Cancer
oligo subset V2.0 (Operon Biotechnologies GmbH, Germany) was
carried out using UltraGAPS-coated glass microarray slides
(Corning B.V. Life Sciences, The Netherlands). The 70mer
oligonucleotide probes were dissolved in Pronto cDNA/Long Oligo
Spotting Solution (Corning) and spotted onto a glass slide with a
Qarray2 microarray spotter (Genetix, UK) and ScoreCard controls
(GE Healthcare). Pre-hybridization, hybridization and washing of
the microarrays were carried out according to manufacturer’s
instructions (Pronto Microarray hybridization kit; Corning). Cy3
and Cy5 fluorescent signals were detected with an Affymetrix 428
laser scanner and the raw TIFF images were analysed for spot
signal quantification and quality evaluation with Blue Fuse
software V3.1 (BlueGnome, Cambridge, UK). The generated data
files were then exported into R (version 2.5.0; http://www.R-
project.org), normalised (Block-median followed by Across Array
Bioconductor LIMMA package (7, 8), ‘bad’ spots (determined by
BlueFuse V3.1, BlueGnome) extracted and analysed using Rank
Product analysis (9, 10), a technique chosen for its robustness
against biological variance such as that caused by tumour and/or
patient experimental designs (9). Genes with a ‘pfp’ (probability
of false prediction) value (9, 10) less than 0.15 were selected as
being significantly up- or down-regulated.
Real-time quantitative PCR. cDNA was made using the ImPromII
reverse transcription system (Promega, Southampton, UK). Real-
time quantitative PCR was performed using the Stratagene
QPCRMX3005P thermal cycler (Stratagene Europe). Reactions
were performed in a 20 μl volume with 5 pmol primers and 4 mM
MgCl2 using Brilliant SYBR Green QPCR Master Mix reagent
(Stratagene). For survivin, the protocol was 10 min 95˚C for
activating the hot start Taq polymerase, then 20 s at 95˚C, 20 s at
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Table I. Baseline clinical comparison of control versus celecoxib-treated
patients.
Parameter Control Celecoxib- Median 
group treated difference
N=13 N=27 (95%  CI and 
interquartile range)
PSA 8.06 (3.47) 8.25 (4.62) 0.197 (–2.30 to 2.69)
*Pathological 2.07 (0.26) 2.10 (0.31) 0.03 (–0.14 to 0.21)
stage
+Gleason sum 6.53 (0.74) 6.33 (0.71) –0.20 (–0.66 to 0.26)
Values shown are the means with the standard deviation shown in
parentheses. *All patients had clinical stage T1c-T2c N0 M0 disease;
+All patients had Gleason sum 6/7.
60˚C and 20s at 72˚C for 45 cycles; for p73, 95˚C for 5 min then
40 cycles of 94˚C 30 s, 60˚C for 30 s, 68˚C for 2 min; for cyclin
B1, 95˚C for 5 min then 40 cycles of 95˚C for 20 s, 60˚C for 
60 s. For SRP72kDa, the protocol was 95˚C for 10 min, then 35
cycles of 95˚C for 60 s, 62˚C for 2 min and 72˚C for 3 min. All
analyses were set up in duplicate and were also repeated on at
least 2 separate occasions. Relative expression of genes was
normalized to that of actin and gene expression in each sample
calculated as 2–ΔΔCr.
Primer sequences were designed using Primer 3 software and
supplied by Invitrogen (Paisley, UK). For survivin: forward:
5’ACCAGGTGAGAAGTGAGGGA-3’, reverse: 5’-AACAGTAG
AGGAGCCAGGGA-3’; for cyclin B1: 5’-CTCCTGTCTGGTG
GGAGGA-3’, reverse 5’-CTGATCCAGAATAACACCTGA-3’; for
P73: forward: 5’-TCTTTCGAGGGTCGCATCTG-3’, reverse: 5’-TCC
CGGTAATGGTCTTCATCAG-3’; for SRP72kDa: forward: 5’-GTCG
AACAGAGGAGGCTTTG-3’, reverse: 5’-CGGGACTTTGGGACTG
TAAA-3’; for β actin forward: 5’-GCATCCACG AAACTACCTTC-
3’, reverse: 5’-CAGGAGGAGCAATGATCTTG-3’.
Statistical analysis. For comparison of all the q-PCR data obtained,
we used the SPSS 12.0.1 program. Comparison of means was
carried out using the one-way ANOVA or equality of means test, as
appropriate. Differences were considered significant if a p-value of
0.05 or less was obtained.
Results
Baseline clinical parameters obtained for control and
celecoxib-treated patients. Data are shown in Table I.
Microarray analysis and Q-PCR validation: For the
microarray part of the study we used a cut-off of ± 50%
change in expression relative to the control arm. Table II lists
the up-regulated genes. The data obtained revealed a list
comprising 24 genes that showed statistically significant (see
methods) >1.5-fold increments between celecoxib-treated
and control untreated patients. A variety of genes with
different functional significance were up-regulated in the
celecoxib-treated patient group. Figure 1 shows the
subsequent q-PCR evaluation of 3 up-regulated genes that
were on the list (cyclin B1, p73 and SRP72kDa). The data
help to verify the microarray analysis with levels of
significance for the variation between control and celecoxib-
treated group as being significant or very close to significant
for SRP72kDa, where a high standard deviation for the levels
of mRNA obtained in the celecoxib-treated patient biopsies
was seen. Table III lists the down-regulated genes. A further
list comprising 3 genes showed significant <0.5-fold
decrease in celecoxib treated versus control patients. Due to
our previous observation that survivin mRNA and protein
were markedly down-regulated in COX-2-expressing human
prostate cancer LNCaP cells (11), we also considered this
gene in our subsequent q-PCR evaluation in the present
study. The mRNA levels proved to be significantly reduced
in patients from the celecoxib-treated group versus controls
(see Figure 1).
Discussion 
In order to investigate the effects of celecoxib on GEPs, we
analysed biopsies from patients treated with celecoxib as
well as control patients. After statistical processing, we
compiled a list of 24 up-regulated and 3 down-regulated
genes in celecoxib-treated versus control arm patients. In
addition, to the gene list, we looked at the anti-apoptotic
factor survivin as this was shown to be a very sensitive
indicator of the effects of celecoxib in COX-2-expressing
prostate cancer cells in our previous studies (11). Due to the
stringent filtering criteria used (spot quality, statistical
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Figure 1. Quantitative PCR data obtained for control, untreated prostate
cancer patients and celecoxib-treated patients. All assays were carried
out at least 3 times and levels of statistical significance were calculated
using SPSS software with p-values of 0.05 and below being considered
significant.
significance as opposed to fold change alone) for the
microarray data analysis, certain genes may not have been
identified. We aimed to look at the survivin gene in our
patient dataset and so performed q-PCR analysis including
other genes that had been identified as being up-regulated in
the celecoxib-treated prostate cancer patients.
A hallmark of cancer cells versus normal cells is
uncontrolled cell division as a consequence of dysregulated
CANCER GENOMICS & PROTEOMICS 6: 93-100 (2009)
96
Table II. Genes statistically significantly up-regulated in celecoxib-treated patients.
Gene accession Gene description Ratio of Probability Ontology
number expression  of false 
celecoxib vs. prediction
control
AK056837 Ribosomal proteinL13a 1.88 0.09 Catalysis of protein synthesis, 
component of ribosomal 60S subunit
NM_000889 Integrin beta 7 1.87 0.05 Receptor involved in immune 
developmental synapse formation
NM_006082 Tubulin, alpha, ubiquitous 1.81 0.13 Protein component of tubulin (along 
with beta tubulin) to form microtubule
NM_000612 Insulin-like growth factor -2 1.81 0.13 Paracrine growth factor, epigenetically 
regulated in prostate cancer
NM_002734 Protein kinase, cAMP-dependent, alpha 1.81 0.10 cAMP regulation; growth factor 
promoting cell growth and transformation
NM-006947 Signal recognition particle 72kDa 1.77 0.08 Signalling pathway involving 
endoplasmic reticulum
NM_003836 Delta-like 1 homolog (drosophila) 1.75 0.12 Member of epidermal growth factor-like 
homeotic protein family, 
immune regulatory function
X58529 Immunoglobulin heavy constant mu 1.74 0.13 Immune modulatory function
NM_000023 Sarcoglycan, alpha (50 kDa dystrophin 1.72 0.11 Critical to the stability of muscle fibre 
associated glycoprotein) membranes and linking of actin to ECM
NM_031966 Cyclin B1 1.71 0.13 Cell cycle regulation, 
tumour suppressor role
NM_005581 Lutheran blood group 1.70 0.12 Member of immunoglobulin 
(Auberger b antigen included) superfamily and receptor for lamin
NM_006256 Protein kinase-C-like 2 1.70 0.13 Essential regulator for entry into 
mitosis and exit from cytokinesis
NM_005427 Tumor protein p73 1.69 0.12 p53-related, tumour suppressor role
NM_006325 RAN, member RAS oncogene family 1.69 0.12 GTP-binding protein, cell cycle and 
DNA synthesis regulation
NM_004494 Hepatoma-derived growth factor 1.69 0.10 Mitogenic and DNA-binding activity, 
(high mobility group protein 1-like) plays a role in cellular proliferation 
and differentiation
NM_014977 KIAA0670 protein/acinus 1.68 0.13 Involved in signal transduction involving 
AKT and susceptibility to caspase- 
mediated apoptosis
NM_001013 Ribosomal protein S9 1.67 0.11 Encodes a protein that comprises 
the 40S ribosome subunit
NM_003299 Tumor rejection antigen (gp96) 1 1.66 0.10 Involved in signal transduction, 
protein folding and degradation
NM_013282 Ubiquitin-like, containing PHD and 1.66 0.12 Member of the RING-finger type E3 
RING finger domains ubiquitin ligases, uses histone 
deacetylase in gene regulation, 
cell cycle role in G1/S transition
NM_001961 Eukaryotic translation elongation factor 2 1.66 0.12 Essential factor for protein synthesis, 
promoting GTP-dependent 
protein translocation
NM_006164 Nuclear factor (erythroid-derived 2)-like 2 1.63 0.13 Encodes basic leucine zipper 
transcription factors
NM_002512 Non-metastatic cells 2, protein (NM23B) 1.57 0.10 Metastasis suppressor function
NM_005845 ATP-binding cassette, sub family C 1.57 0.11 Androgen-regulated gene, ATP- 
(CFTR/MRP) member 4 binding cassette transporter family member
NM_000224 Keratin 18 1.54 0.13 Type 1 intermediate filament chain component.
cyclins and cyclin-dependent kinases (CDKs). CDKs are
necessary for proper progression of the cell cycle through
mitosis. A study by Gomez et al. (12) established a positive
correlation between cyclin B1 protein and apoptotic cell death.
Stable overexpression of cyclin B1 in LNCaP and PC-3 cells
induced a chemosensitizing effect and conversely an SiRNA
approach was shown to decrease apoptosis. In the present
study, we were able to demonstrate a clear increase in cyclin
B1 in prostate cancer tissue taken from celecoxib-treated
patients, an effect confirmed using q-PCR analysis. Our data
are suggestive of a proapoptotic effect orchestrated by
induction of cyclin B1 along with other factors attributable to
celecoxib administered to prostate cancer patients.
SRP72kDa was one of the genes up-regulated by 1.8-fold
in the celecoxib group. SRP72kDa is essential for protein
translocation from the cytoplasm to the endoplasmic
reticulum. It has also been shown to undergo post-
translational modification during apoptosis (13), and its role
in death receptor-mediated processes has recently been
reported (14). Hence, SRP72kDa plays a role in protein
trafficking which appears to support DR4-mediated
apoptosis, associated with the extrinsic pathway of apoptosis.
Nuclear factor (erythroid-derived 2)-like 2 (NFED2) was
up-regulated in the celecoxib group by 1.6-fold. NFED2 has
been shown to be stimulated by BRCA overexpression;
BRCA up-regulates the expression of multiple genes
involved in the cytoprotective antioxidant response (15).
Moreover, these findings may be of relevance to prostate
cancer, in addition to inheritable breast cancer with that
mutation and consequential dysregulation of BRCA is
frequently associated, as it is associated with increased risk
for the development of this malignancy in susceptible
populations (16). NFED2 is, therefore, an antioxidant
response transcription factor and thus preserves genome
integrity. Prostate cancer at its various stages can be
described as an inflammatory process associated in part with
an imbalance of reactive oxygen species (ROS) versus
antioxidant processes (2). Hence, the effects of celecoxib in
promoting antioxidant processes are particularly relavant to
the problem of prostate cancer and add further support to its
application in this disease setting.
The p73 tumour suppressor gene was up-regulated by 1.7-
fold in the patients treated with celecoxib. In its role as a
tumour suppressor, p73 is involved in growth suppression
and cell cycle arrest. However, the alternate spliced
(truncated) forms of the gene product can undermine or
overlap p53 function and have been reported in prostate
cancer (17). Although the precise tumour suppressor role for
p73 and its interaction with p53 and apoptosis remains
unclear, we show a clear induction of wild-type p73 as a
consequence of celecoxib treatment in the present study. A
recent report by Beitzinger et al. (18) lends further support
to the hypothesis that p73 has a tumour suppressor role,
independent of the p53 tumour suppressor, and is associated
with inhibition of malignant transformation by limiting
anchorage-independent growth.
A gene that was shown to be reduced in celecoxib-treated
prostate cancer tissue was myosin light chain kinase.
Inhibition of this enzyme has been shown to reduce the
growth of mammary and prostate cancer cells in in vitro and
in vivo models with chemosensitization of cells to the
effects of etoposide (19). Thus, the effect of celcoxib has
been shown to reduce tumorigenic potential in prostate
cancer cells and this has been borne out in a clinical setting
in the present study. We have previously shown a very
significant reduction of survivin in celecoxib-treated COX-
2-expressing prostate cancer cells (11) and this is in good
agreement with the present study. Survivin is a regulator of
apoptosis that plays a significant role in cancer and is
expressed in most human tumours whereas in normal
differentiated tissues it is more or less undetectable.
Krajewska et al. (20) showed that elevated IAPs were a
common feature of prostate cancer including PIN, but they
showed no relationship with Gleason grade or PSA levels.
Krysan et al. (21) showed that survivin levels correlated
positively with COX-2 expression levels in non-small lung
cancer (NSCLC) cells and COX-2 was shown to modulate
survivin ubiquitination and stabilisation. A report by Yoo et
Sooriakumaran et al: Celecoxib Effects on Gene Expression Profiling of Prostate Cancer
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Table III. Genes statistically significantly down-regulated in celecoxib-treated patients.
Gene accession Gene description Ratio of Probability Ontology
number expression  of false 
celecoxib vs. prediction
control
NM_000062 Serine (or cysteine) proteinase inhibitor, 0.47 0.001 Involved in regulation of the complement cascade
clade G (C1 inhibitor), member 1
NM_053025 Myosin, light polypeptide kinase 0.44 0.002 Facilitates myosin and actin interaction, 
tumour-promoting function
NM_003186 Transgelin 0.38 0.001 Transformation and shape change sensitive 
protein in fibroblasts, function unclear
al. (22) described the effects of aspirin (a non-specific-
COX-2 inhibitor) in promoting TRAIL-induced apoptosis
via down-regulation of survivin due to inhibition of E2F-1
binding activity to the survivin promoter region. 
A study by Febbo et al. (23) described a trial involving
weekly docetaxel for 6 months in patients with high-risk
localized prostate cancer in the neoadjuvant setting, prior
to RP. A gene expression profiling approach was also used
by these authors to assess the biological effects of the
chemotherapy on prostate cancer tissues taken from those
patients taken at RP and compared with untreated controls.
The magnitude of the gene expression changes seen
between the two groups of patients in that particular report
was of a similar order to that in the present study, which
essentially compared two groups (control and celecoxib-
treated) of cancerous tissue, rather than normal adjacent
versus cancerous tissue, where higher differentials of gene
expression have been reported. Nevertheless, the study by
Febbo et al. (23), taken together with the data described
herein, suggest that microarray analysis following
neoadjuvant therapy in prostate cancer is feasible and can
also form a valuable line of enquiry when exploring the
effects of novel targeted therapy. With regard to celecoxib,
other clinical studies have shown the beneficial effects in
prostate cancer using different endpoints. For example,
Pruthi et al. (24) demonstrated stabilisation of PSA levels
in patients who had been treated with celecoxib for various
time periods of up to 18 months, following radiation
therapy or radical prostatectomy. 
We have successfully completed a randomized clinical
trial investigating celecoxib in patients with primary,
localized prostate cancer prior to RP. Overall, this study
suggests that celecoxib has anticancer effects affecting cell
proliferation, promotion of apoptosis, cell communication
and integrity, and supports our earlier findings (5, 11). Our
results suggest that celecoxib is worthy of further
investigation as a novel therapy in prostate cancer. 
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